Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer.

Kuip EJM, Oldenmenger WH, Thijs-Visser MF, de Bruijn P, Oosten AW, Oomen-de Hoop E, Koolen SLW, Van der Rijt CCD, Mathijssen RHJ.

PLoS One. 2018 Jun 8;13(6):e0198289. doi: 10.1371/journal.pone.0198289. eCollection 2018.

2.

Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.

Kuip EJM, Oldenmenger WH, Visser-Thijs MF, de Bruijn P, Oomen-de Hoop E, Mathijssen RHJ, Van der Rijt CCD, Koolen SW.

Oncotarget. 2018 Apr 6;9(26):18269-18276. doi: 10.18632/oncotarget.24812. eCollection 2018 Apr 6.

3.

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.

Gao B, Lu Y, Nieuweboer AJM, Xu H, Beesley J, Boere I, de Graan AM, de Bruijn P, Gurney H, J Kennedy C, Chiew YE, Johnatty SE, Beale P, Harrison M, Luccarini C, Conroy D, Mathijssen RHJ, R Harnett P, Balleine RL, Chenevix-Trench G, Macgregor S, de Fazio A.

Sci Rep. 2018 Jan 24;8(1):1508. doi: 10.1038/s41598-018-19590-w.

4.

OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.

Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S.

J Clin Invest. 2018 Feb 1;128(2):816-825. doi: 10.1172/JCI96160. Epub 2018 Jan 16.

5.

Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne.

Lourbakos A, Yau N, de Bruijn P, Hiller M, Kozaczynska K, Jean-Baptiste R, Reza M, Wolterbeek R, Koeks Z, Ayoglu B, de Klerk D, Campion G, Zaharieva I, Nadarajah VD, Nilsson P, Al-Khalili Szigyarto C, Muntoni F, Lochmüller H, Verschuuren JJ, Goemans N, Tulinius M, Niks EH, de Kimpe S, Aartsma-Rus A, 't Hoen PAC, Spitali P.

Sci Rep. 2017 Dec 20;7(1):17888. doi: 10.1038/s41598-017-17982-y.

6.

Hydrochlorothiazide and acute urinary acidification: The "voltage hypothesis" of ENaC-dependent H+ secretion refuted.

Ayasse N, de Bruijn PIA, Berg P, Sørensen MV, Leipziger J.

Acta Physiol (Oxf). 2018 May;223(1):e13013. doi: 10.1111/apha.13013. Epub 2017 Dec 29.

PMID:
29226589
7.

Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma.

de Bruijn P, Kuip EJM, Lam MH, Mathijssen RHJ, Koolen SLW.

J Pharm Biomed Anal. 2018 Feb 5;149:475-481. doi: 10.1016/j.jpba.2017.11.035. Epub 2017 Nov 17.

PMID:
29182997
8.

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.

Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336. Epub 2017 Nov 17.

PMID:
29150561
9.

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.

Hu S, Mathijssen RHJ, de Bruijn P, Baker SD, Sparreboom A.

Br J Cancer. 2017 Aug 22;117(5):e3. doi: 10.1038/bjc.2017.217. Epub 2017 Jul 13.

10.

Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD.

Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.

11.

A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.

Oosten AW, Abrantes JA, Jönsson S, Matic M, van Schaik RHN, de Bruijn P, van der Rijt CCD, Mathijssen RHJ.

Clin Pharmacokinet. 2017 Jul;56(7):733-746. doi: 10.1007/s40262-016-0471-7.

12.

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.

Bins S, Eechoute K, Kloth JS, de Man FM, Oosten AW, de Bruijn P, Sleijfer S, Mathijssen RH.

Clin Pharmacokinet. 2017 Mar;56(3):305-310. doi: 10.1007/s40262-016-0441-0.

13.

Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.

de Morrée E, van Soest R, Aghai A, de Ridder C, de Bruijn P, Ghobadi Moghaddam-Helmantel I, Burger H, Mathijssen R, Wiemer E, de Wit R, van Weerden W.

Prostate. 2016 Jul;76(10):927-36. doi: 10.1002/pros.23182. Epub 2016 Mar 21.

PMID:
26997363
14.

Hyperaldosteronism after decreased renal K+ excretion in KCNMB2 knockout mice.

Larsen CK, Jensen IS, Sorensen MV, de Bruijn PI, Bleich M, Praetorius HA, Leipziger J.

Am J Physiol Renal Physiol. 2016 May 15;310(10):F1035-46. doi: 10.1152/ajprenal.00010.2016. Epub 2016 Mar 9.

15.

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.

van Leeuwen RW, Peric R, Hussaarts KG, Kienhuis E, IJzerman NS, de Bruijn P, van der Leest C, Codrington H, Kloover JS, van der Holt B, Aerts JG, van Gelder T, Mathijssen RH.

J Clin Oncol. 2016 Apr 20;34(12):1309-14. doi: 10.1200/JCO.2015.65.2560. Epub 2016 Feb 8. Erratum in: J Clin Oncol. 2016 Aug 10;34(23):2806.

PMID:
26858332
16.

Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.

Oosten AW, Abrantes JA, Jönsson S, de Bruijn P, Kuip EJ, Falcão A, van der Rijt CC, Mathijssen RH.

Eur J Clin Pharmacol. 2016 Apr;72(4):459-67. doi: 10.1007/s00228-015-2005-x. Epub 2016 Jan 14.

17.

Context-dependent alarm signalling in an insect.

de Bruijn PJ, Egas M, Sabelis MW, Groot AT.

J Evol Biol. 2016 Mar;29(3):665-71. doi: 10.1111/jeb.12813. Epub 2016 Jan 12.

18.

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.

Binkhorst L, Bannink M, de Bruijn P, Ruit J, Droogendijk H, van Alphen RJ, den Boer TD, Lam MH, Jager A, van Gelder T, Mathijssen RH.

Clin Pharmacokinet. 2016 Feb;55(2):249-55. doi: 10.1007/s40262-015-0315-x.

19.

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.

Nieuweboer AJ, Smid M, de Graan AM, Elbouazzaoui S, de Bruijn P, Eskens FA, Hamberg P, Martens JW, Sparreboom A, de Wit R, van Schaik RH, Mathijssen RH.

Pharmacogenomics J. 2016 Nov;16(6):519-524. doi: 10.1038/tpj.2015.66. Epub 2015 Sep 8.

PMID:
26345519
20.

Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.

Huisman SA, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, IJzermans JN, Wiemer EA, Mathijssen RH, de Bruin RW.

Br J Pharmacol. 2016 Mar;173(5):804-14. doi: 10.1111/bph.13317. Epub 2016 Feb 8.

21.

Predicting paclitaxel-induced neutropenia using the DMET platform.

Nieuweboer AJ, Smid M, de Graan AJ, Elbouazzaoui S, de Bruijn P, Martens JW, Mathijssen RH, van Schaik RH.

Pharmacogenomics. 2015;16(11):1231-41. doi: 10.2217/pgs.15.68. Epub 2015 Aug 12.

PMID:
26265135
22.

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

de Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Br J Clin Pharmacol. 2015 Sep;80(3):560-8. doi: 10.1111/bcp.12707. Epub 2015 Aug 12.

23.

Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair.

Drooger JC, Jager A, Lam MH, den Boer MD, Sleijfer S, Mathijssen RH, de Bruijn P.

J Pharm Biomed Anal. 2015 Oct 10;114:416-25. doi: 10.1016/j.jpba.2015.06.018. Epub 2015 Jun 12.

PMID:
26119504
24.

Lysosomal Sequestration Determines Intracellular Imatinib Levels.

Burger H, den Dekker AT, Segeletz S, Boersma AW, de Bruijn P, Debiec-Rychter M, Taguchi T, Sleijfer S, Sparreboom A, Mathijssen RH, Wiemer EA.

Mol Pharmacol. 2015 Sep;88(3):477-87. doi: 10.1124/mol.114.097451. Epub 2015 Jun 24.

25.

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.

Binkhorst L, Kloth JSL, de Wit AS, de Bruijn P, Lam MH, Chaves I, Burger H, van Alphen RJ, Hamberg P, van Schaik RHN, Jager A, Koch BCP, Wiemer EAC, van Gelder T, van der Horst GTJ, Mathijssen RHJ.

Breast Cancer Res Treat. 2015 Jul;152(1):119-128. doi: 10.1007/s10549-015-3452-x. Epub 2015 Jun 7.

26.

Furosemide-induced urinary acidification is caused by pronounced H+ secretion in the thick ascending limb.

de Bruijn PI, Larsen CK, Frische S, Himmerkus N, Praetorius HA, Bleich M, Leipziger J.

Am J Physiol Renal Physiol. 2015 Jul 15;309(2):F146-53.

27.

[Ca2+]i Oscillations and IL-6 Release Induced by α-Hemolysin from Escherichia coli Require P2 Receptor Activation in Renal Epithelia.

Christensen MG, Fagerberg SK, de Bruijn PI, Bjaelde RG, Jakobsen H, Leipziger J, Skals M, Praetorius HA.

J Biol Chem. 2015 Jun 5;290(23):14776-84. doi: 10.1074/jbc.M115.639526. Epub 2015 Apr 24.

28.

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.

Kloth JS, Binkhorst L, de Wit AS, de Bruijn P, Hamberg P, Lam MH, Burger H, Chaves I, Wiemer EA, van der Horst GT, Mathijssen RH.

Clin Pharmacokinet. 2015 Aug;54(8):851-8. doi: 10.1007/s40262-015-0239-5.

29.

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.

Hamberg P, Mathijssen RH, de Bruijn P, Leonowens C, van der Biessen D, Eskens FA, Sleijfer S, Verweij J, de Jonge MJ.

Cancer Chemother Pharmacol. 2015 Feb;75(2):365-71. doi: 10.1007/s00280-014-2655-x. Epub 2014 Dec 23.

PMID:
25533184
30.

P2X receptors trigger intracellular alkalization in isolated perfused mouse medullary thick ascending limb.

de Bruijn PI, Bleich M, Praetorius HA, Leipziger J.

Acta Physiol (Oxf). 2015 Jan;213(1):277-84. doi: 10.1111/apha.12417. Epub 2014 Nov 24.

31.

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors.

van der Biessen DA, Burger H, de Bruijn P, Lamers CH, Naus N, Loferer H, Wiemer EA, Mathijssen RH, de Jonge MJ.

Clin Cancer Res. 2014 Sep 15;20(18):4776-83. doi: 10.1158/1078-0432.CCR-14-0325. Epub 2014 Jul 14.

32.

Effects of kinship or familiarity? Small thrips larvae experience lower predation risk only in groups of mixed-size siblings.

de Bruijn PJ, Sabelis MW, Egas M.

Behav Ecol Sociobiol. 2014;68:1029-1035. Epub 2014 Apr 1.

33.

Influence of drug formulation on OATP1B-mediated transport of paclitaxel.

Nieuweboer AJ, Hu S, Gui C, Hagenbuch B, Ghobadi Moghaddam-Helmantel IM, Gibson AA, de Bruijn P, Mathijssen RH, Sparreboom A.

Cancer Res. 2014 Jun 1;74(11):3137-45. doi: 10.1158/0008-5472.CAN-13-3634. Epub 2014 Apr 22.

34.

Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.

ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, Huitema AD.

Br J Clin Pharmacol. 2014 Sep;78(3):572-86. doi: 10.1111/bcp.12388.

35.

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.

Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A.

Br J Cancer. 2014 Feb 18;110(4):894-8. doi: 10.1038/bjc.2013.811. Epub 2014 Jan 7. Erratum in: Br J Cancer. 2017 Jul 13;:.

36.

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.

Hamberg P, Boers-Sonderen MJ, van der Graaf WT, de Bruijn P, Suttle AB, Eskens FA, Verweij J, van Herpen CM, Sleijfer S.

Br J Cancer. 2014 Feb 18;110(4):888-93. doi: 10.1038/bjc.2013.798. Epub 2013 Dec 24.

37.

Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance.

Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A.

Clin Pharmacol Ther. 2013 Nov;94(5):585-92. doi: 10.1038/clpt.2013.145. Epub 2013 Jul 17.

38.

The issue of non-specific binding of cabazitaxel.

de Bruijn P, Moghaddam-Helmantel IM, Loos WJ, Mathijssen RH, Wiemer EA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Aug 1;932:74-5. doi: 10.1016/j.jchromb.2013.06.016. Epub 2013 Jun 17. No abstract available.

PMID:
23831699
39.

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Clin Cancer Res. 2013 Jun 15;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786. Epub 2013 May 2.

40.

Long-term prospective population PK study in GIST patients--response.

Mathijssen RH, de Bruijn P, Eechoute K, Sparreboom A.

Clin Cancer Res. 2013 Feb 15;19(4):950. doi: 10.1158/1078-0432.CCR-12-3807. Epub 2013 Feb 5. No abstract available.

41.

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A.

Clin Cancer Res. 2012 Aug 15;18(16):4433-40. Epub 2012 Jun 18.

42.

Basolateral P2X receptors mediate inhibition of NaCl transport in mouse medullary thick ascending limb (mTAL).

Marques RD, de Bruijn PI, Sorensen MV, Bleich M, Praetorius HA, Leipziger J.

Am J Physiol Renal Physiol. 2012 Feb 15;302(4):F487-94. doi: 10.1152/ajprenal.00570.2011. Epub 2011 Nov 23.

43.

Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.

de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, Wiemer EA, Loos WJ.

J Pharm Biomed Anal. 2012 Feb 5;59:117-22. doi: 10.1016/j.jpba.2011.10.010. Epub 2011 Oct 24.

PMID:
22079047
44.

Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.

Binkhorst L, Mathijssen RH, Ghobadi Moghaddam-Helmantel IM, de Bruijn P, van Gelder T, Wiemer EA, Loos WJ.

J Pharm Biomed Anal. 2011 Dec 15;56(5):1016-23. doi: 10.1016/j.jpba.2011.08.002. Epub 2011 Aug 5.

PMID:
21872414
45.

Complex odor from plants under attack: herbivore's enemies react to the whole, not its parts.

van Wijk M, de Bruijn PJ, Sabelis MW.

PLoS One. 2011;6(7):e21742. doi: 10.1371/journal.pone.0021742. Epub 2011 Jul 13.

46.

Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.

Schiavon G, Eechoute K, Mathijssen RH, de Bruijn P, van der Bol JM, Verweij J, Sleijfer S, Loos WJ.

J Clin Pharmacol. 2012 Jul;52(7):1115-20. doi: 10.1177/0091270011409235. Epub 2011 May 20. No abstract available.

PMID:
21602518
47.

Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study.

Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA.

Clin Cancer Res. 2011 Jan 15;17(2):353-62. doi: 10.1158/1078-0432.CCR-10-1636. Epub 2011 Jan 11.

48.

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

van der Bol JM, Loos WJ, de Jong FA, van Meerten E, Konings IR, Lam MH, de Bruijn P, Wiemer EA, Verweij J, Mathijssen RH.

Eur J Cancer. 2011 Apr;47(6):831-8. doi: 10.1016/j.ejca.2010.11.030. Epub 2011 Jan 6.

49.

Automated analysis of neuronal morphology, synapse number and synaptic recruitment.

Schmitz SK, Hjorth JJ, Joemai RM, Wijntjes R, Eijgenraam S, de Bruijn P, Georgiou C, de Jong AP, van Ooyen A, Verhage M, Cornelisse LN, Toonen RF, Veldkamp WJ.

J Neurosci Methods. 2011 Feb 15;195(2):185-93. doi: 10.1016/j.jneumeth.2010.12.011. Epub 2010 Dec 15. Erratum in: J Neurosci Methods. 2011 Apr 15;197(1):190. Veldkamp, Wouter [corrected to Veldkamp, Wouter J H].

50.

Effectiveness and cost-effectiveness of early assisted discharge for chronic obstructive pulmonary disease exacerbations: the design of a randomised controlled trial.

Utens CM, Goossens LM, Smeenk FW, van Schayck OC, van Litsenburg W, Janssen A, van Vliet M, Seezink W, Demunck DR, van de Pas B, de Bruijn PJ, van der Pouw A, Retera JM, de Laat-Bierings P, van Eijsden L, Braken M, Eijsermans R, Rutten-van Mölken MP.

BMC Public Health. 2010 Oct 18;10:618. doi: 10.1186/1471-2458-10-618.

Supplemental Content

Loading ...
Support Center